Skip to main
CLPT
CLPT logo

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc is poised for continued growth, evidenced by a strong 17% topline growth at the close of 2023 and a significant reduction in cash burn, which indicates enhanced financial stability. The company is expected to achieve at least 20% revenue growth in 2024, driven by an expanding partnership base and higher-value service offerings within its Biologics segment. Furthermore, the recent key product approvals and record system installations, coupled with supportive clinical publications, position ClearPoint Neuro favorably for sustained profitability and market advancement.

Bears say

ClearPoint Neuro has demonstrated a significant reduction in cash burn over the course of 2023, decreasing from $5.8 million in the first quarter to $1.2 million by the fourth quarter. Despite this improvement in cash management, the company's reliance on continuously lowering cash burn may indicate underlying challenges in revenue generation and overall business growth. Furthermore, without a clear path to increasing revenues alongside these cost reductions, concerns persist about the sustainability of operations and investment appeal moving forward.

CLPT has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 3 analysts, CLPT has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.